Cibinqo effective option for atopic dermatitis regardless of previous Dupixent use
Click Here to Manage Email Alerts
Cibinqo safely and effectively treated moderate to severe atopic dermatitis among patients regardless of any previous treatment with Dupixent, according to data published in the Journal of the American Academy of Dermatology.
Vivian Y. Shi, MD, of the University of Arkansas for Medical Sciences, and colleagues wrote that treatment options have been limited for moderate to severe atopic dermatitis (AD) that is unresponsive to topical agents.
They also noted that Cibinqo (abrocitinib, Pfizer) and Dupixent (dupilumab, Regeneron/Sanofi) have different mechanisms of action in AD.
To examine the safety and efficacy of abrocitinib, Shi and colleagues enrolled patients from previous JADE phase 3 studies into a phase 3 long-term extension study, which included comparative results between abrocitinib and dupilumab. They randomly assigned patients to receive oral abrocitinib 200 mg or 100 mg once daily.
Among patients who previously responded to dupilumab, 93.5% in the 200 mg group and 90.2% in the 100 mg group achieved a 75% or greater improvement in EASI after 12 weeks of treatment. Additionally, 89.7% in the 200 mg group and 81.6% in the 100 mg group achieved a 4-point or greater improvement in Peak Pruritus Numerical Rating Scale.
Among nonresponder patients, 47.2% in the 200 mg group and 35.2% in the 100 mg group achieved an IGA score of 0/1. Nonresponder patients also achieved a Peak Pruritus Numerical Rating Scale improvement of 4 points or more among 77.3% of those in the 200 mg group and among 37.8% of those in the 100 mg.
Serious adverse reactions related to treatment occurred in three patients, including one case of vertigo, one case of pancreatitis at day 26 and one case of eczema herpeticum.
The safety of abrocitinib was consistent with previous phase 3 studies with few adverse events overall. The most common adverse events included nasopharyngitis, nausea, acne, headache and upper respiratory tract infection. Additionally, all cases of conjunctivitis were mild and did not lead to discontinuation.
“Abrocitinib represents an effective systemic oral treatment option for patients with moderate to severe AD, regardless of prior dupilumab response status,” Shi and colleagues wrote. “Patients with AD that fail to respond to dupilumab, who cannot tolerate or experience AEs with dupilumab or who prefer an oral therapy may consider abrocitinib treatment.”
Collapse
Read more about
Click Here to Manage Email Alerts